** Brokerage Bernstein raises PT on medical device maker Insulet Corp PODD.O to $335 from $315
** New PT represents 18.5% upside to stock's last close
** Says it maintains "outperform" rating, adding its PT reflects increasing profitability
** Brokerage pointed several growth drivers for co, including integration of its Omnipod insulin pumps with Dexcom's DXCM.O G7 continuous glucose monitor, iOS compatibility with G5 devices, and launch an advanced version of insulin system
** Co's lead product is the Omnipod system, a tubeless, wearable insulin pump
** Co's revenue growth forecast of 17% to 21% is "conservative" and "we like the setup for 2025" - Bernstein
** Brokerage sees potential for growth driven by sales in type 2 diabetes market and expanding profit margins
** Stock has risen ~47% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.